Development of Bruton’s Tyrosine Kinase Inhibitors for Rheumatoid Arthritis

Author(s): Jiahui Lv, Jingde Wu*, Feng He, Ying Qu, Qiuqiong Zhang, Chenggong Yu

Journal Name: Current Medicinal Chemistry

Volume 25 , Issue 42 , 2018

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor


Rheumatoid Arthritis (RA) is a chronic autoimmune disease and becomes one of the major causes of disability and work force loss. The presence of abnormal B cell and autoantibodies produced by most RA patients, primarily ACPA and RF, indicate that the function of B cell was involved in the development of RA disease. Accordingly, the drug targeting B cell has become a hot spot in the treatment of RA. Studies have shown that Bruton's tyrosine kinase (BTK) is involved in the regulation of B cell proliferation and activation process. Some small molecule BTK inhibitors have shown excellent inhibition in biological activity analysis and animal models. Therefore, this review will briefly introduce BTK and its role in cell signaling and overview recent progress of BTK inhibitors for RA treatment.

Keywords: BTK inhibitor, RA, B cell, activity, anti-inflammatory, structure.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2018
Published on: 16 March, 2018
Page: [5847 - 5859]
Pages: 13
DOI: 10.2174/0929867325666180316121951
Price: $65

Article Metrics

PDF: 128
HTML: 13
PRC: 1